open access

Vol 14, No 1 (2020)
Case report
Published online: 2020-05-08
Get Citation

TP53 mutation in children with therapy-related myelodysplastic syndrome/acute myeloid leukemia after rhabdomyosarcoma treatment

Ewelina Gowin, Danuta Januszkiewicz-Lewandowska
DOI: 10.5603/PMPI.2020.0007
·
Palliat Med Pract 2020;14(1):58-62.

open access

Vol 14, No 1 (2020)
Case report
Published online: 2020-05-08

Abstract

After successful treatment of childhood malignancy, development of second malignancy (SM) is the most
devastating and potentially life-threatening sequelae of it. In the past 12 years there have been no cases
of therapy-related myelodysplastic syndrome/acute myeloid leukemia (t-MDS/AML) among 80 children
treated for soft tissue sarcomas (STS) in the Department of Paediatric Oncology, Haematology, and Bone
Marrow Transplantation. Given the rarity of recognition of t-MDS/AML in children after treatment of
cancers, it was decided to analyse in detail the therapy and cytogenetic and molecular results in two boys
aged 9 and 10 years old, diagnosed with t-MDS/AML secondary to rhabdomyosarcoma. In both of them
TP53 mutation was found.

Palliat Med Pract 2020; 14, 1: 58–62

Abstract

After successful treatment of childhood malignancy, development of second malignancy (SM) is the most
devastating and potentially life-threatening sequelae of it. In the past 12 years there have been no cases
of therapy-related myelodysplastic syndrome/acute myeloid leukemia (t-MDS/AML) among 80 children
treated for soft tissue sarcomas (STS) in the Department of Paediatric Oncology, Haematology, and Bone
Marrow Transplantation. Given the rarity of recognition of t-MDS/AML in children after treatment of
cancers, it was decided to analyse in detail the therapy and cytogenetic and molecular results in two boys
aged 9 and 10 years old, diagnosed with t-MDS/AML secondary to rhabdomyosarcoma. In both of them
TP53 mutation was found.

Palliat Med Pract 2020; 14, 1: 58–62

Get Citation

Keywords

acute myeloid leukaemia, children, myelodysplastic syndrome, rhabdomyosarcoma, TP53 mutation

About this article
Title

TP53 mutation in children with therapy-related myelodysplastic syndrome/acute myeloid leukemia after rhabdomyosarcoma treatment

Journal

Palliative Medicine in Practice

Issue

Vol 14, No 1 (2020)

Article type

Case report

Pages

58-62

Published online

2020-05-08

DOI

10.5603/PMPI.2020.0007

Bibliographic record

Palliat Med Pract 2020;14(1):58-62.

Keywords

acute myeloid leukaemia
children
myelodysplastic syndrome
rhabdomyosarcoma
TP53 mutation

Authors

Ewelina Gowin
Danuta Januszkiewicz-Lewandowska

References (26)
  1. Hijiya N, Ness KK, Ribeiro RC, et al. Acute leukemia as a secondary malignancy in children and adolescents: current findings and issues. Cancer. 2009; 115(1): 23–35.
  2. Pedersen-Bjergaard J, Andersen MK, Christiansen DH. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood. 2000; 95(11): 3273–3279.
  3. Pedersen-Bjergaard J, Andersen MK, Andersen MT, et al. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood. 2002; 99(6): 1909–1912.
  4. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20): 2391–2405.
  5. Hasle H. Myelodysplastic and myeloproliferative disorders of childhood. Hematology Am Soc Hematol Educ Program. 2016; 2016(1): 598–604.
  6. Hong M, He G. The 2016 Revision to the World Health Organization Classification of Myelodysplastic Syndromes. J Transl Int Med. 2017; 5(3): 139–143.
  7. Ogasawara T, Yasuyama M, Kawauchi K. Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia (M2). Am J Hematol. 2005; 79(2): 136–141.
  8. Navid F, Billups C. Second Cancers in patients with ESFT. Eur J Cancer. 2008; 44: 983–991.
  9. Bhatia S, Krailo MD, Chen Z, et al. Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group. Blood. 2007; 109(1): 46–51.
  10. Andersen MK, Christiansen DH, Pedersen-Bjergaard J. Centromeric breakage and highly rearranged chromosome derivatives associated with mutations of TP53 are common in therapy-related MDS and AML after therapy with alkylating agents: an M-FISH study. Genes Chromosomes Cancer. 2005; 42(4): 358–371.
  11. Sans-Sabrafen J, Buxó-Costa J, Woessner S, et al. Myelodysplastic syndromes and malignant solid tumors: analysis of 21 cases. Am J Hematol. 1992; 41(1): 1–4.
  12. el Rouby S, Thomas A, Costin D, et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood. 1993; 82(11): 3452–3459.
  13. Andersen MK, Christiansen DH, Pedersen-Bjergaard J. Centromeric breakage and highly rearranged chromosome derivatives associated with mutations of TP53 are common in therapy-related MDS and AML after therapy with alkylating agents: an M-FISH study. Genes Chromosomes Cancer. 2005; 42(4): 358–371.
  14. Nadji M, Meng L, Lin L, et al. Detection of p53 gene abnormality by sequence analysis of archival paraffin tissue. A comparison with fresh-frozen specimens. Diagn Mol Pathol. 1996; 5(4): 279–283.
  15. Meng L, Lin L, Zhang H, et al. Multiple mutations of the p53 gene in human mammary carcinoma. Mutat Res. 1999; 435(3): 263–269.
  16. Belickova M, Vesela J, Jonasova A, et al. TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes. Oncotarget. 2016; 7(24): 36266–36279.
  17. Ruijs MWG, Verhoef S, Rookus MA, et al. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet. 2010; 47(6): 421–428.
  18. Seki M, Nishimura R, Yoshida K, et al. Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma. Nat Commun. 2015; 6: 7557.
  19. Hettmer S, Archer NM, Somers GR, et al. Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers. Cancer. 2014; 120(7): 1068–1075.
  20. Takahashi Y, Oda Y, Kawaguchi KI, et al. Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma. Mod Pathol. 2004; 17(6): 660–669.
  21. Kobos R, Steinherz PG, Kernan NA, et al. Allogeneic hematopoietic stem cell transplantation for pediatric patients with treatment-related myelodysplastic syndrome or acute myelogenous leukemia. Biol Blood Marrow Transplant. 2012; 18(3): 473–480.
  22. Niemeyer CM, Kratz CP, Hasle H. Pediatric myelodysplastic syndromes. Curr Treat Options Oncol. 2005; 6(3): 209–214.
  23. Strahm B, Locatelli F, Bader P, et al. Reduced intensity conditioning in unrelated donor transplantation for refractory cytopenia in childhood. Bone Marrow Transplant. 2007; 40(4): 329–333.
  24. Welch JS, Petti AA, Miller CA, et al. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. N Engl J Med. 2016; 375(21): 2023–2036.
  25. Cseh AM, Niemeyer CM, Yoshimi A, et al. Therapy with low-dose azacitidine for MDS in children and young adults: a retrospective analysis of the EWOG-MDS study group. Br J Haematol. 2016; 172(6): 930–936.
  26. Singhal D, Wee LiY, Kutyna MM, et al. The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution. Leukemia. 2019; 33(12): 2842–2853.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Medycyna Paliatywna w Praktyce dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl